Synonym
Flupirtine HCl; Flupirtine hydrochloride;
IUPAC/Chemical Name
Carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester, hydrochloride
InChi Key
WBAZQELGBFQHPE-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H17FN4O2.ClH/c1-2-22-15(21)19-12-7-8-13(20-14(12)17)18-9-10-3-5-11(16)6-4-10;/h3-8H,2,9H2,1H3,(H,19,21)(H3,17,18,20);1H
SMILES Code
O=C(OCC)NC1=CC=C(NCC2=CC=C(F)C=C2)N=C1N.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
|
Solvent |
mg/mL |
mM |
| Solubility |
| Soluble in DMSO |
0.0 |
100.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
340.78
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Maalouf K, Makoukji J, Saab S, Makhoul NJ, Carmona AV, Kinarivala N, Ghanem N, Trippier PC, Boustany RM. Exogenous Flupirtine as Potential Treatment for CLN3 Disease. Cells. 2020 Aug 11;9(8):1872. doi: 10.3390/cells9081872. PMID: 32796515; PMCID: PMC7464162.
2: Nair AS. Flupirtine: A Less-Explored, Neglected Nonopioid Analgesic. Anesth Analg. 2018 Apr;126(4):1425. doi: 10.1213/ANE.0000000000002807. PMID: 29381516.
3: Devulder J. Flupirtine in pain management: pharmacological properties and clinical use. CNS Drugs. 2010 Oct;24(10):867-81. doi: 10.2165/11536230-000000000-00000. PMID: 20839897.
4: Kaplan S, Ehlken B, Hamann X. Drug utilization patterns of flupirtine following implementation of risk minimization measures in Germany. Curr Med Res Opin. 2019 Aug;35(8):1397-1403. doi: 10.1080/03007995.2019.1594743. Epub 2019 Apr 23. PMID: 30865848.
5: Nair AS. Flupirtine use in the era of risk minimization measures. Curr Med Res Opin. 2019 Aug;35(8):1479. doi: 10.1080/03007995.2019.1618113. Epub 2019 Jun 17. PMID: 31074657.
6: Szelenyi I. Flupirtine, a re-discovered drug, revisited. Inflamm Res. 2013 Mar;62(3):251-8. doi: 10.1007/s00011-013-0592-5. Epub 2013 Jan 16. PMID: 23322112.
7: Osborne NN, Cazevieille C, Wood JP, Nash MS, Pergande G, Block F, Kosinski C, Schwarz M. Flupirtine, a nonopioid centrally acting analgesic, acts as an NMDA antagonist. Gen Pharmacol. 1998 Mar;30(3):255-63. doi: 10.1016/s0306-3623(97)00355-8. PMID: 9510072.
8: Zhang F, Liu S, Jin L, Tang L, Zhao X, Yang T, Wang Y, Huo B, Liu R, Li H. Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain. Pharmacology. 2020;105(7-8):471-476. doi: 10.1159/000505934. Epub 2020 Feb 14. PMID: 32062659.
9: Puljak L. Flupirtine, an Effective Analgesic, but Hepatotoxicity Should Limit Its Use. Anesth Analg. 2018 Jul;127(1):309-310. doi: 10.1213/ANE.0000000000003355. PMID: 29596091.
10: Surur AS, Bock C, Beirow K, Wurm K, Schulig L, Kindermann MK, Siegmund W, Bednarski PJ, Link A. Flupirtine and retigabine as templates for ligand-based drug design of KV7.2/3 activators. Org Biomol Chem. 2019 May 8;17(18):4512-4522. doi: 10.1039/c9ob00511k. PMID: 30990511.
